50 Recruiting Recurrent Acute Myeloid Leukemia Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Recurrent Acute Myeloid Leukemia
Related Conditions
Top Recruiting Recurrent Acute Myeloid Leukemia Studies
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
📍 Children's Hospital of Alabama — Birmingham, Alabama
View Study & Checklist ➔CPX-351 Plus Enasidenib for Relapsed AML
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia
📍 Children's Hospital of Alabama — Birmingham, Alabama
View Study & Checklist ➔BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
📍 Roswell Park Cancer Institute — Buffalo, New York
View Study & Checklist ➔CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔Tazemetostat and Palbociclib With CPX-351for R/R AML
📍 Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
View Study & Checklist ➔